Cite

    Bohlega, S. et al. (n.d.). Expert opinion on clinical experience with subcutaneous interferon beta‐1a in multiple sclerosis patients with different disease activity profiles. Neurology and clinical neuroscience. 7 (5), pp. 260-266. [Online].